Health Care · Pharmaceutical Preparations · Nasdaq · CIK 715446 · FYE Oct 31 · Prices AT CLOSE 2026-07-30 (USD) — end-of-day, never a live or intraday quote
Last $3.56Day +2.30%Mkt cap $121M1Y +12.7%Off 52W high −34.8%Vol (1Y) 73.3%
Daily closing price, split-adjusted to the current basis; 3y shown of 2,524 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest2.5% of sh out |
| Days to cover3.1d |
| 13F net flow (QoQ)−0.02% |
| Top-10 13F concentration81.1% |
| Next report (est.)2026-09-11 |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| Earnings (TTM)-$10.0M |
| ROE−62.2% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD+14.1% |
| 1Y+12.7% |
| 3Y−0.8% |
| 5Y−19.5% |
| 10Y+11.9% |
| Since incept. (ann.)+1.1% |
Total return through 2026-07-30 · series begins 2016-07-11. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)73.3% |
| Ann. volatility (3Y)69.7% |
| Sharpe (1Y)0.55 |
| Sharpe (3Y)0.34 |
| Max drawdown (1Y)−52.9% |
| Max drawdown (3Y)−57.6% |
| Beta (3Y vs SPY)0.79 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC | 1.3M | $3M | 3.92% | new |
| Laird Norton Wetherby Trust Company, LLC | 566,327 | $1M | 1.69% | −3.7% |
| UBS Group AG | 551,637 | $1M | 1.65% | +20.2% |
| D.A. DAVIDSON & CO. | 539,272 | $1M | 1.61% | +0.0% |
| GEODE CAPITAL MANAGEMENT, LLC | 364,731 | $941,440 | 1.09% | +3.9% |
| VANGUARD FIDUCIARY TRUST CO | 191,074 | $492,971 | 0.57% | new |
| MARSHALL WACE, LLP | 173,179 | $446,800 | 0.52% | +327.0% |
| BlackRock, Inc. | 170,103 | $438,865 | 0.51% | +3.7% |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-04-30 | 2026-06-10 | −$0.07 | — | — | — |
| 2026-01-31 | 2026-03-09 | −$0.08 | — | — | — |
| 2025-07-31 | 2025-09-10 | −$0.07 | — | — | — |
| 2025-04-30 | 2025-05-28 | −$0.09 | — | — | — |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-09-11 is ESTIMATED from filing cadence (median gap 93d) — not company-confirmed.
